HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes
Nicole A. Doria‐RoseMark K. LouderZhongjia YangSijy O’DellMartha NasonStephen D. SchmidtKrisha McKeeMichael S. SeamanRobert T. BailerJohn R. Mascola
78
Citation
41
Reference
10
Related Paper
Citation Trend
Abstract:
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are being considered for passive prevention of infection. We analyzed the interaction of MAbs to two independent epitopes on the viral envelope glycoprotein. Potently neutralizing MAbs to the CD4 binding site and V1V2 region displayed no in vitro cross-competition and displayed additive, though not synergistic, neutralization activity. Predicted neutralization coverage of a combination of two MAbs reached 97% on a 208-isolate panel.Abstract While there are various attempts to administer COVID-19-convalescent plasmas to SARS-CoV-2-infected patients, neither appropriate approach nor clinical utility has been established. We examined the presence and temporal changes of the neutralizing activity of IgG fractions from 43 COVID-19-convalescent plasmas using cell-based assays with multiple endpoints. IgG fractions from 27 cases (62.8%) had significant neutralizing activity and moderately to potently inhibited SARS-CoV-2 infection in cell-based assays; however, no detectable neutralizing activity was found in 16 cases (37.2%). Approximately half of the patients (~ 41%), who had significant neutralizing activity, lost the neutralization activity within ~ 1 month. Despite the rapid decline of neutralizing activity in plasmas, good amounts of SARS-CoV-2-S1-binding antibodies were persistently seen. The longer exposure of COVID-19 patients to greater amounts of SARS-CoV-2 elicits potent immune response to SARS-CoV-2, producing greater neutralization activity and SARS-CoV-2-S1-binding antibody amounts. The dilution of highly-neutralizing plasmas with poorly-neutralizing plasmas relatively readily reduced neutralizing activity. The presence of good amounts of SARS-CoV-2-S1-binding antibodies does not serve as a surrogate ensuring the presence of good neutralizing activity. In selecting good COVID-19-convalescent plasmas, quantification of neutralizing activity in each plasma sample before collection and use is required.
Convalescent plasma
Cite
Citations (50)
We have characterized and mapped variable and conserved neutralization epitopes of serogroup A strains of aquatic birnaviruses. Epitope mapping using monoclonal antibodies (MAbs) and Escherichia coli-expressed deletion fragments of VP2 of the N1 strain of infectious pancreatic necrosis virus (IPNV) demonstrated that two variable epitopes, H8 and B9, depend on the variable region between amino acid 204–330. A conserved neutralization epitope, F2, was shown to depend on the same region as epitopes H8 and B9 but was additionally dependent on amino acids between 153–203. The neutralization epitopes H8, B9 and F2 were also shown to overlap by a competitive binding assay. One conserved neutralization epitope, AS-1, was not exposed on any of the recombinant VP2 deletion fragments and was therefore not possible to map. However, the MAbs AS-1 and F2 were partly competitive indicating that these epitopes are overlapping. All neutralization epitopes were independent of a conserved non-neutralization epitope, E4. Our results demonstrate that the central third of VP2 contains several partly overlapping neutralization epitopes, both variable and conserved among serogroup A strains of IPNV.
Cite
Citations (53)
Studies of neutralizing antibodies in HIV-1 infected individuals provide insights into the quality of the response that should be possible to elicit with vaccines and ways to design effective immunogens. Some individuals make high titres of exceptional broadly reactive neutralizing antibodies that are of particular interest; however, more modest responses may be a reasonable goal for vaccines. We performed a large cross-sectional study to determine the spectrum of neutralization potency and breadth that is seen during chronic HIV-1 infection.Neutralization potency and breadth were assessed with genetically and geographically diverse panels of 205 chronic HIV-1 sera and 219 Env-pseudotyped viruses representing all major genetic subtypes of HIV-1.Neutralization was measured by using Tat-regulated luciferase reporter gene expression in TZM-bl cells. Serum-neutralizing activity was compared with a diverse set of human mAbs that are widely considered to be broadly neutralizing.We observed a uniform continuum of responses, with most sera displaying some level of cross-neutralization, and approximately 50% of sera neutralizing more than 50% of viruses. Titres of neutralization (potency) were highly correlated with breadth. Many sera had breadth comparable to several of the less potent broadly neutralizing human mAbs.These results help clarify the spectrum of serum-neutralizing activity induced by HIV-1 infection and that should be possible to elicit with vaccines. Importantly, most people appear capable of making low to moderate titres of broadly neutralizing antibodies. Additional studies of these relatively common responses might provide insights for practical and feasible vaccine designs.
Cite
Citations (342)
Infectivity
Antibody titer
Coxsackievirus
Cytopathic effect
Cite
Citations (15)
Neutralizing antibodies are a major correlate of protection for many viruses including the novel coronavirus SARS-CoV-2. Thus, vaccine candidates should potently induce neutralizing antibodies to render effective protection from infection. A variety of in vitro assays for the detection of SARS-CoV-2 neutralizing antibodies has been described. However, validation of the different assays against each other is important to allow comparison of different studies. Here, we compared four different SARS-CoV-2 neutralization assays using the same set of patient samples. Two assays used replication competent SARS-CoV-2, a focus forming assay and a TCID50-based assay, while the other two assays used replication defective lentiviral or vesicular stomatitis virus (VSV)-based particles pseudotyped with SARS-CoV-2 spike. All assays were robust and produced highly reproducible neutralization titers. Titers of neutralizing antibodies correlated well between the different assays and with the titers of SARS-CoV-2 S-protein binding antibodies detected in an ELISA. Our study showed that commonly used SARS-CoV-2 neutralization assays are robust and that results obtained with different assays are comparable.
Antibody titer
Coronavirus
Cite
Citations (122)
Cite
Citations (1)
V3 loop
Cite
Citations (20)
Variable loops V1V2 and V3 present on the apex of the trimeric HIV-1 envelope (Env) spike play opposing roles in antibody recognition, as these loops not only contain conserved neutralizing epitopes but also participate in epitope masking. This study investigated the different factors that play role in modulating the exposure of V2i epitopes as compared to the better characterized V3 epitopes. V2i (V2-intergrin) are conformation-dependent epitopes that encompass the integrin α4β7-binding motif and other conserved elements in the V1V2 loop of HIV-1 Env gp120. First, we asked whether CD4-induced Env conformational changes affect V2i epitopes similar to V3. CD4 treatment of BaL and JRFL pseudoviruses increased their neutralization sensitivity to V3 but not to the V2i mAbs. Second, the contribution of N-glycans on masking V2i versus V3 epitopes was evaluated by testing neutralization of viruses produced in the presence of a glycosidase inhibitor, kifunensine. Pseudoviruses grown in kifunensine were more sensitive to neutralization by V3 but not V2i mAbs. Finally, we evaluated the time-dependent dynamics of the V2i and V3 epitopes. Extending the time of virus-mAb interaction, before adding target cells, increased virus neutralization by some V2i mAbs and all V3 mAbs tested. Importantly, with the extended incubation time, significant neutralization was detected against resistant Tier 2 HIV-1 isolates. The levels of neutralization achieved with the longer incubation time, but not the standard 1hr incubation, correlated with relative affinity of the V2i mAbs as measured by half maximal binding to gp120. These data demonstrate that distinct mechanisms contribute to the masking of V3 and V2i epitopes. Although the biologic significance of neutralization detectable with prolonged incubation time remains unknown, this study reveals the importance of the structural dynamics of V2i and V3 epitopes in determining HIV-1 neutralization by antibodies targeting these sites.
V3 loop
Cite
Citations (2)
Summary The 7 S and 19 S rabbit antibodies to herpes simplex virus (HSV) from early and late (hyperimmune) sera differed in their ability to sensitize virus for subsequent neutralization by either complement (C′) or anti-γ-globulin (GAR). The early 7 S and 19 S antibodies showed low to negligible neutralizing activity in the absence of C′ or GAR. When C′ was added, however, both of these antibodies showed enhanced neutralizing activity. The early 7 S but not the early 19 S antibody was also capable of sensitizing virus for subsequent neutralization by GAR. The late 19 S antibody could neutralize virus in the absence of C′ or GAR, but its activity was enhanced in the presence of C′ or GAR. The late 7 S antibody showed high neutralizing activity in the absence of C′ or GAR. In the presence of C′, the neutralization rate constants (K) but not the neutralization titers of the late 7 S antibody were enhanced. In contrast, the neutralization titers of the late 7 S antibody were enhanced approximately threefold with GAR. The neutralizing activity of the early and late 19 S antibodies with C′ or GAR was sensitive to inactivation by 2-ME. Similarly, the neutralizing activity with C′ of the early 7 S antibody and the enhanced rate of neutralization with C′ of the late 7 S antibody were sensitive to inactivation by 2-ME. In contrast, 2-ME did not reduce the neutralization titers of the early and late 7 S antibodies in the presence of GAR.
Cite
Citations (101)